

E1 *sub F1* *cont.* 6. (Three Times Amended) An isolated DNA which codes for a peptide having serine protease or domain activity, and is hybridizable with DNA that codes for the serine protease or domain, as claimed in claim 21 under stringent conditions.

E2 *sub F2* 9. (Twice Amended) A process for preparing serine protease or domain comprising culturing a host cell as claimed in claim 8, and recovering serine protease or domain.

sub F3 14. (Twice Amended) An isolated DNA which codes for the serine protease or domain as claimed in claim 22.

E3 15. (Twice Amended) An isolated DNA which codes for the serine protease or domain as claimed in claim 23.

16. (Twice Amended) An isolated DNA which codes for the serine protease or domain as claimed in claim 24.

E4 21. (Amended) An isolated serine protease consisting of the amino acid sequence indicated in SEQ ID NO: 6.

sub F37

22. (Amended) A serine protease domain consisting of an amino acid sequence from amino acid No. 578 to 822 indicated in SEQ ID NO: 6.

E4

23. (Amended) A kringle domain consisting of an amino acid sequence from amino acid No. 40 to 112 indicated in SEQ ID NO: 6.

F

24. (Amended) A scavenger receptor cysteine-rich(SRCR) domain consisting of an amino acid sequence selected from the group consisting of: the amino acid sequence from amino acid No. 117 to 217, from amino acid No. 227 to 327, from amino acid No. 334 to 433, or from amino acid No. 447 to 547 indicated in SEQ ID NO: 6.

25. (Amended) A process for screening physiologically active substances comprising the steps of measuring inhibitory or activating activity of the substances using the serine protease as claimed in claim 21, or measuring binding affinity of the substances to the serine protease or domain as claimed in claim 21.

26. (Amended) A process for screening physiologically active substances comprising the steps of measuring inhibitory or activating activity of the substance using the serine protease as claimed in claim 21, or measuring binding affinity of the substance to the serine protease as claimed in claim 21, that is prepared by using a DNA which codes for the serine protease or domain as claimed in claim 21.

27. (Amended) A process for screening physiologically active substances comprising the steps of measuring inhibitory or activating activity of the substance using the serine protease as claimed in claim 21, or measuring binding affinity of the substance to the serine protease as claimed in claim 21, that is prepared by using a DNA which codes for a peptide having serine protease or domain activity, and is hybridizable with DNA that codes for the serine protease or domain as claimed in claim 21 under stringent conditions.

E4 28. (Amended) An isolated DNA which codes for a peptide having domain activity, and is hybridizable with DNA that codes for the domain as claimed in claim 22, under stringent conditions.

29. (Amended) An isolated DNA which codes for a peptide having domain activity, and is hybridizable with DNA that codes for the domain as claimed in claim 23, under stringent conditions.

30. (Amended) An isolated DNA which codes for a peptide having domain activity, and is hybridizable with DNA that codes for the domain as claimed in claim 24, under stringent conditions.

E5 sub F6 44. (Amended) A process for preparing domain comprising culturing a host cell as claimed in claim 37, and recovering domain or their partial peptides.

45. (Amended) A process for preparing domain comprising culturing a host cell as claimed in claim 38, and recovering domain.

46. (Amended) A process for preparing domain comprising culturing a host cell as claimed in claim 39, and recovering domain.

47. (Amended) A process for preparing serine protease comprising culturing a host cell as claimed in claim 40, and recovering serine protease.

48. (Amended) A process for preparing domain comprising culturing a host cell as claimed in claim 41, and recovering domain.

49. (Amended) A process for preparing domain comprising culturing a host cell as claimed in claim 42, and recovering domain.

50. (Amended) A process for preparing domain comprising culturing a host cell as claimed in claim 43, and recovering domain.

51. (Amended) A process for screening physiologically active substances comprising the steps of measuring inhibitory or activating activity of the substance using

Sub F7
cont. / F
the domain as claimed in claim 22, or measuring binding affinity of the substance to the domain as claimed in claim 22.

52. (Amended) A process for screening physiologically active substances comprising the steps of measuring inhibitory or activating activity of the substance using the domain as claimed in claim 23, or measuring binding affinity of the substance to the domain as claimed in claim 23.

F5
53. (Amended) A process for screening physiologically active substances comprising the steps of measuring inhibitory or activating activity of the substance using the domain as claimed in claim 24, or measuring binding affinity of the substance to the domain as claimed in claim 24. F

54. (Amended) A process for screening physiologically active substances comprising the steps of measuring inhibitory or activating activity of the substance using the domain as claimed in claim 22, or measuring binding affinity of the substance to the domain as claimed in claim 22, that prepared by using the DNA which codes for the serine protease or domain as claimed in claim 22.

55. (Amended) A process for screening physiologically active substances comprising the steps of measuring inhibitory or activating activity of the substance using

the domain as claimed in claim 23, or measuring binding affinity of the substance to the domain as claimed in claim 23, that prepared by using the DNA which codes for the serine protease or domain as claimed in claim 23.

ES 56. (Amended) A process for screening physiologically active substances comprising the steps of measuring inhibitory or activating activity of the substance using the domain as claimed in claim 24, or measuring binding affinity of the substance to the domain as claimed in claim 24, that prepared by using the DNA which codes for the serine protease or domain as claimed in claim 24. F

57. (Amended) A process for screening physiologically active substances comprising the steps of measuring inhibitory or activating activity of the substance using the domain as claimed in claim 22, or measuring binding affinity of the substance to the domain as claimed in claim 22, that prepared by using the DNA which codes for a peptide having domain activity, and is hybridizable with DNA that codes for the domain as claimed in claim 22, under stringent conditions.

58. (Amended) A process for screening physiologically active substances comprising the steps of measuring inhibitory or activating activity of the substance using the domain as claimed in claim 23, or measuring binding affinity of the substance to the domain as claimed in claim 23, that prepared by using the DNA which codes for a peptide

having domain activity, and is hybridizable with DNA that codes for the domain as claimed in claim 23, under stringent conditions.

FE 59. (Amended) A process for screening physiologically active substances comprising the steps of measuring inhibitory or activating activity of the substance using the domain as claimed in claim 24, or measuring binding affinity of the substance to the domain as claimed in claim 24, that prepared by using the DNA which codes for a peptide having domain activity, and is hybridizable with DNA that codes for the domain as claimed in claim 24, under stringent conditions.
